Covered recipient · General Payments record
FIRAS B BADIN
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$193,466.89
322 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $138,708.00 | 40 |
| Travel and Lodging | $25,843.59 | 49 |
| Consulting Fee | $23,248.50 | 14 |
| Food and Beverage | $5,639.71 | 217 |
| Education | $27.09 | 2 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 3 of 7; records 101–150 of 322 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
FIRAS B BADIN
NPI 1588828693 · CMS profile ID 343881
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
LEXINGTON, KY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 7; records 101–150 of 322 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1588828693?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- FIRAS B BADIN, NPI 1588828693, CMS profile ID 343881. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 322 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588828693?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). FIRAS B BADIN, NPI 1588828693, CMS profile ID 343881. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 322 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588828693?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- FIRAS B BADIN, NPI 1588828693, CMS profile ID 343881, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 7; records 101–150 of 322 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1588828693?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
322 matching records · $193,466.89 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 322.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $14.64 | 09/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078651932 | CMS |
| Incyte Corporation | $17.07 | 09/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141276928 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,283.00 | 09/25/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101217276 | CMS |
| Astellas Pharma US Inc | $17.52 | 09/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139395345 | CMS |
| E.R. Squibb & Sons, L.L.C. | $11.88 | 09/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101217272 | CMS |
| JAZZ PHARMACEUTICALS INC. | $4,340.00 | 09/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150222228 | CMS |
| PFIZER INC. | $2.12 | 09/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130894911 | CMS |
| PFIZER INC. | $9.44 | 09/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130894915 | CMS |
| Genmab U.S., Inc. | $12.26 | 09/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126826600 | CMS |
| Genmab U.S., Inc. | $5.30 | 09/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126826594 | CMS |
| Novartis Pharmaceuticals Corporation | $8.30 | 09/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086739013 | CMS |
| Novartis Pharmaceuticals Corporation | $19.45 | 09/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086739015 | CMS |
| PFIZER INC. | $21.27 | 09/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131359366 | CMS |
| Regeneron Healthcare Solutions, Inc. | $659.00 | 09/19/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114003201 | CMS |
| Regeneron Healthcare Solutions, Inc. | $659.00 | 09/19/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114003203 | CMS |
| Merck Sharp & Dohme LLC | $16.49 | 09/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141709793 | CMS |
| Lilly USA, LLC | $20.16 | 09/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134976380 | CMS |
| Alexion Pharmaceuticals, Inc. | $28.92 | 09/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110531407 | CMS |
| JAZZ PHARMACEUTICALS INC. | $8.95 | 09/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150222258 | CMS |
| JAZZ PHARMACEUTICALS INC. | $16.13 | 09/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150222260 | CMS |
| Janssen Biotech, Inc. | $22.13 | 09/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078650019 | CMS |
| E.R. Squibb & Sons, L.L.C. | $665.93 | 09/12/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101217290 | CMS |
| E.R. Squibb & Sons, L.L.C. | $467.14 | 09/12/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101217294 | CMS |
| E.R. Squibb & Sons, L.L.C. | $243.03 | 09/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101217274 | CMS |
| E.R. Squibb & Sons, L.L.C. | $583.58 | 09/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101217278 | CMS |
| E.R. Squibb & Sons, L.L.C. | $179.52 | 09/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101217280 | CMS |
| Genmab U.S., Inc. | $28.00 | 09/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126826596 | CMS |
| ABBVIE INC. | $21.70 | 09/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103261869 | CMS |
| ABBVIE INC. | $675.00 | 09/09/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103131599 | CMS |
| JAZZ PHARMACEUTICALS INC. | $379.35 | 09/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150222234 | CMS |
| JAZZ PHARMACEUTICALS INC. | $89.40 | 09/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150222284 | CMS |
| Regeneron Healthcare Solutions, Inc. | $42.33 | 09/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114003199 | CMS |
| Janssen Scientific Affairs, LLC | $113.70 | 09/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078850820 | CMS |
| Genentech USA, Inc. | $15.32 | 09/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133011564 | CMS |
| JAZZ PHARMACEUTICALS INC. | $4,340.00 | 09/03/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150222226 | CMS |
| Kite Pharma, Inc. | $15.01 | 08/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1128612263 | CMS |
| Daiichi Sankyo Inc. | $15.35 | 08/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089395801 | CMS |
| EMD Serono, Inc. | $13.42 | 08/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120262088 | CMS |
| PFIZER INC. | $720.00 | 08/30/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132058098 | CMS |
| Daiichi Sankyo Inc. | $16.59 | 08/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089395799 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2.27 | 08/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101217266 | CMS |
| JAZZ PHARMACEUTICALS INC. | $82.68 | 08/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150222282 | CMS |
| ABBVIE INC. | $4.91 | 08/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103261867 | CMS |
| ABBVIE INC. | $1.72 | 08/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103261865 | CMS |
| Janssen Biotech, Inc. | $20.66 | 08/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078651676 | CMS |
| ARRAY BIOPHARMA INC | $19.46 | 08/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131900847 | CMS |
| Daiichi Sankyo Inc. | $20.11 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089395797 | CMS |
| JAZZ PHARMACEUTICALS INC. | $73.04 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150222280 | CMS |
| Merck Sharp & Dohme LLC | $13.37 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141709937 | CMS |
| AstraZeneca Pharmaceuticals LP | $31.22 | 08/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110543143 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $4,730.94 | 11 |
| PY2025 | Principal investigator | $611,999.68 | 149 |
| PY2024 | Principal investigator | $536,455.75 | 128 |
| PY2023 | Principal investigator | $951,304.72 | 73 |
| PY2022 | Principal investigator | $948,134.72 | 82 |
| PY2021 | Principal investigator | $722,869.16 | 116 |
| PY2020 | Principal investigator | $785,041.40 | 102 |
| PY2019 | Principal investigator | $589,534.05 | 17 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
160 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,497.86 | 12/31/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast | No dispute reported | 06/30/2026 | 1232927735 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $58,962.30 | 12/26/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation | No dispute reported | 06/30/2026 | 1236530148 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,202.00 | 12/15/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344191 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,202.00 | 12/15/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344195 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $24,945.00 | 12/15/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion | No dispute reported | 06/30/2026 | 1236001749 |
| Principal investigator 1 | ABBVIE INC. | $3,913.70 | 12/04/2025 | Covered Recipient Teaching Hospital BAPTIST HEALTH LEXINGTON | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202406087 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,000.00 | 11/26/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190329261 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,500.00 | 11/26/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190329291 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,178.00 | 11/26/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334517 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $577.00 | 11/19/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344193 |
| Principal investigator 1 | Genmab A/S | $1,000.00 | 11/17/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEMS INC. | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235927667 |
| Principal investigator 1 | Genmab A/S | $1,139.00 | 11/17/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEMS INC. | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235927671 |
| Principal investigator 1 | Genmab A/S | $14,500.00 | 11/17/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEMS INC. | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235927675 |
| Principal investigator 1 | Genmab A/S | $2,036.00 | 11/17/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEMS INC. | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235927679 |
| Principal investigator 1 | Genmab A/S | $2,000.00 | 11/17/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEMS INC. | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235927683 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 11/12/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344197 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 11/12/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344199 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.75 | 11/12/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344217 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 11/12/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344219 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.55 | 11/12/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344221 |
| Principal investigator 1 | ABBVIE INC. | $7,381.78 | 11/05/2025 | Covered Recipient Teaching Hospital BAPTIST HEALTH LEXINGTON | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202406079 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,465.00 | 11/03/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344201 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,951.00 | 11/03/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344203 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,202.00 | 11/03/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344205 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,756.00 | 11/03/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344207 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,202.00 | 11/03/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344209 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,951.00 | 11/03/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344211 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,202.00 | 11/03/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344213 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $900.00 | 11/03/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344215 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,082.84 | 10/27/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion | No dispute reported | 06/30/2026 | 1236001751 |
| Principal investigator 1 | ABBVIE INC. | $20,468.71 | 10/09/2025 | Covered Recipient Teaching Hospital BAPTIST HEALTH LEXINGTON | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202406076 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,690.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344083 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,507.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344085 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,202.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344087 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,668.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344089 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,597.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344091 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,918.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344093 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,465.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344109 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,477.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344111 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,477.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344113 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,477.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344115 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,595.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344117 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,756.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344119 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,597.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344121 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,507.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344123 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,597.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344125 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,894.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344127 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,202.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344129 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,918.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344131 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,704.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344177 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,465.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344181 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,202.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344187 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,202.00 | 09/17/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344189 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,000.00 | 09/12/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344095 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $750.00 | 09/12/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344097 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $780.00 | 09/12/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344099 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $14,000.00 | 09/12/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344101 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $43.00 | 09/12/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344103 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 09/12/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344105 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $94.00 | 09/12/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344107 |
| Principal investigator 1 | ABBVIE INC. | $12,690.33 | 09/04/2025 | Covered Recipient Teaching Hospital BAPTIST HEALTH LEXINGTON | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202406073 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $700.00 | 08/28/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192098688 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,380.00 | 08/28/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192098698 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $905.80 | 08/28/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192150308 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $686.00 | 08/28/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192150317 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,900.00 | 08/28/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192150322 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $35.00 | 08/28/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192150326 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,820.00 | 08/28/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192150339 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,800.00 | 08/28/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192154225 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $385.00 | 08/28/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192154232 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $453.60 | 08/28/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192154243 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,362.00 | 08/28/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192154247 |
| Principal investigator 1 | Genentech, Inc. | $27,000.00 | 08/19/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211541039 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,795.40 | 08/12/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192098693 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344081 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344133 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $13.20 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344135 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.75 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344137 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344139 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344141 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344143 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344145 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344147 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344149 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344151 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344153 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344155 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344157 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344159 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344161 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344163 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.05 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344165 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.55 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344167 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344169 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344171 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344173 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $104.25 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344175 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $57.75 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344179 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344183 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344185 |
| Principal investigator 1 | ABBVIE INC. | $9,197.40 | 07/22/2025 | Covered Recipient Teaching Hospital BAPTIST HEALTH LEXINGTON | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202406069 |
| Principal investigator 1 | ABBVIE INC. | $874.30 | 07/02/2025 | Covered Recipient Teaching Hospital BAPTIST HEALTH LEXINGTON | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202406066 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,092.00 | 06/20/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192150335 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $385.00 | 06/20/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192154228 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,073.60 | 06/11/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192150313 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $10,689.00 | 06/11/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192154237 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,000.00 | 06/05/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233734864 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $376.00 | 06/05/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca | No dispute reported | 06/30/2026 | 1233734866 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $27,066.28 | 05/16/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) | No dispute reported | 06/30/2026 | 1185545449 |
| Principal investigator 1 | BeiGene, Ltd. | $2,450.00 | 05/14/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325038 |
| Principal investigator 1 | BeiGene, Ltd. | $4,710.00 | 05/09/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320702 |
| Principal investigator 1 | BeiGene, Ltd. | $5,805.00 | 05/09/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320722 |
| Principal investigator 1 | BeiGene, Ltd. | $2,730.00 | 05/09/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325036 |
| Principal investigator 1 | BeiGene, Ltd. | $8,100.00 | 05/09/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325050 |
| Principal investigator 1 | BeiGene, Ltd. | $3,114.00 | 05/09/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190325054 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,800.00 | 04/28/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192150330 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,160.00 | 04/28/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192150342 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $18,200.00 | 04/28/2025 | Non-covered Recipient Entity BAPTIST HEALTHCARE SYSTEM INC | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192154250 |
| Principal investigator 1 | ABBVIE INC. | $7,400.00 | 04/24/2025 | Covered Recipient Teaching Hospital BAPTIST HEALTH LEXINGTON | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202406055 |
| Principal investigator 1 | ABBVIE INC. | $3,120.00 | 04/24/2025 | Covered Recipient Teaching Hospital BAPTIST HEALTH LEXINGTON | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202406059 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,500.00 | 04/16/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metast | No dispute reported | 06/30/2026 | 1232927565 |
| Recipient | GlaxoSmithKline, LLC. | $67.84 | 04/15/2025 | Covered Recipient Physician | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192159741 |
| Recipient | GlaxoSmithKline, LLC. | $18.44 | 04/15/2025 | Covered Recipient Physician | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192159745 |
| Recipient | GlaxoSmithKline, LLC. | $29.59 | 04/15/2025 | Covered Recipient Physician | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192159771 |
| Principal investigator 1 | Eli Lilly and Company | $1,751.54 | 03/25/2025 | Non-covered Recipient Entity BAPTIST HEALTH MEDICAL GROUP INC | A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 | No dispute reported | 06/30/2026 | 1187880883 |
| Recipient | GlaxoSmithKline, LLC. | $3,833.21 | 03/14/2025 | Covered Recipient Physician | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192154255 |
| Recipient | GlaxoSmithKline, LLC. | $45.72 | 03/14/2025 | Covered Recipient Physician | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192154258 |
| Recipient | GlaxoSmithKline, LLC. | $36.42 | 03/14/2025 | Covered Recipient Physician | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192159749 |
| Recipient | GlaxoSmithKline, LLC. | $37.82 | 03/14/2025 | Covered Recipient Physician | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192159754 |
| Recipient | GlaxoSmithKline, LLC. | $616.84 | 03/14/2025 | Covered Recipient Physician | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192159759 |
| Recipient | GlaxoSmithKline, LLC. | $12.57 | 03/14/2025 | Covered Recipient Physician | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192159763 |
| Recipient | GlaxoSmithKline, LLC. | $21.47 | 03/14/2025 | Covered Recipient Physician | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192159767 |
| Recipient | GlaxoSmithKline, LLC. | $11.02 | 03/14/2025 | Covered Recipient Physician | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE | No dispute reported | 06/30/2026 | 1192159776 |
| Principal investigator 1 | Novocure GmbH | $23,128.00 | 03/12/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | EF-36 a pilot, randomized, open-label study evaluating the safety and effectiveness of Tumor Treating Fields (TTFields) with pembrolizumab for first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). | No dispute reported | 06/30/2026 | 1250868004 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.75 | 02/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344039 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 02/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344041 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 02/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344043 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 02/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344045 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 02/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344047 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 02/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344049 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.60 | 02/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344055 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 02/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344073 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 02/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344077 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 02/11/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344079 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $91,051.37 | 01/29/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1185545445 |
| Principal investigator 3 | AstraZeneca Pharmaceuticals LP | $29,663.57 | 01/22/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced Stage III, Unresectable Non-small Cell Lung Cancer NSCLC | No dispute reported | 06/30/2026 | 1185545447 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $154.65 | 01/10/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344033 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $75.00 | 01/10/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344035 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $44.70 | 01/10/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344037 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.80 | 01/10/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344051 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4.25 | 01/10/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344053 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $29.25 | 01/10/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344057 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.15 | 01/10/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344059 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/10/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344061 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/10/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344063 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/10/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344065 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/10/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344067 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/10/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344069 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $86.30 | 01/10/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344071 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/10/2025 | Covered Recipient Teaching Hospital Baptist Health Lexington | DS7300-188 | No dispute reported | 06/30/2026 | 1223344075 |